[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].
Jiang Q, Zhao D, Jin J, Wu D, Meng F, Hu J, Liu B, DU X, Liu T, Li Y, Hou M, Han X, Shen Z, Ma J.
Jiang Q, et al.
Zhonghua Xue Ye Xue Za Zhi. 2015 Aug;36(8):651-5. doi: 10.3760/cma.j.issn.0253-2727.2015.08.005.
Zhonghua Xue Ye Xue Za Zhi. 2015.
PMID: 26462633
Free PMC article.
Clinical Trial.
Chinese.
OBJECTIVE: To evaluate the early hematologic, cytogenetic and molecular responses in newly diagnosed patients with chronic myelogenous leukemia in chronic phase(CML-CP)and initially treated with a generic imatinib(Xinwei), manufactured by Jiansu Hansoh Pharmaceutical Group …
OBJECTIVE: To evaluate the early hematologic, cytogenetic and molecular responses in newly diagnosed patients with chronic myelogenous leuke …